ScreenerHero

MSB Mesoblast Limited

ASX · AU · Healthcare · Biotechnology · mesoblast.com
—Mkt Cap: —P/E: —

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized ce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value1.76B USD
Revenue (TTM)83.10M USD
Gross Profit71.58M USD
Net Income (TTM)-39.74M USD
Revenue/Share0.09 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees108
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000MSB8
Valuation
P/E (Trailing)—
P/E (Forward)16.90
PEG0.13
EV/EBITDA-57.13
EV/Revenue21.19
P/S21.40
P/B3.14
EPS (TTM)-0.06
EPS (Forward)0.12
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin86.14%
Oper. Margin-33.28%
EBITDA Margin-37.09%
Profit Margin-47.82%
ROE-10.12%
ROA-7.44%
Growth
Revenue Growth390.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.29M USD
CapEx (TTM)620.59K USD
FCF Margin-43.22%
FCF Yield—
Net Debt16.88M USD
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity0.22
Current Ratio2.44
Quick Ratio1.98
Book Value/Sh0.63 AUD
Cash/Share0.08 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.637 AUD
Target Range2.900 AUD – 4.450 AUD
# Analysts3
Ownership
Shares Out.1.30B
Float861.10M
Insiders36.27%
Institutions17.45%
Technical
SMA 502.208 AUD
SMA 2002.223 AUD
Beta0.86
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)2.80M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—